146 related articles for article (PubMed ID: 11120940)
1. Pharmacokinetic and pharmacodynamic study of the human immunodeficiency virus protease inhibitor amprenavir after multiple oral dosing.
Sadler BM; Gillotin C; Lou Y; Stein DS
Antimicrob Agents Chemother; 2001 Jan; 45(1):30-7. PubMed ID: 11120940
[TBL] [Abstract][Full Text] [Related]
2. Steady-state pharmacokinetics of amprenavir coadministered with ritonavir in human immunodeficiency virus type 1-infected patients.
Goujard C; Vincent I; Meynard JL; Choudet N; Bollens D; Rousseau C; Demarles D; Gillotin C; Bidault R; Taburet AM
Antimicrob Agents Chemother; 2003 Jan; 47(1):118-23. PubMed ID: 12499178
[TBL] [Abstract][Full Text] [Related]
3. A dose-ranging study to evaluate the antiretroviral activity and safety of amprenavir alone and in combination with abacavir in HIV-infected adults with limited antiretroviral experience.
Schooley RT; Clumeck N; Haubrich R; Thompson M; Danner SA; van Der Ende ME; Sereni D; Antunes F; Blake D; Myers RE; Tisdale M; Millard J; Mustafa N; Nacci P
Antivir Ther; 2001 Jun; 6(2):89-96. PubMed ID: 11491421
[TBL] [Abstract][Full Text] [Related]
4. Amprenavir and ritonavir plasma concentrations in HIV-infected patients treated with fosamprenavir/ritonavir with various degrees of liver impairment.
Seminari E; De Bona A; Gentilini G; Galli L; Schira G; Gianotti N; Uberti-Foppa C; Soldarini A; Dorigatti F; Lazzarin A; Castagna A
J Antimicrob Chemother; 2007 Oct; 60(4):831-6. PubMed ID: 17684056
[TBL] [Abstract][Full Text] [Related]
5. Amprenavir: a new human immunodeficiency virus type 1 protease inhibitor.
Fung HB; Kirschenbaum HL; Hameed R
Clin Ther; 2000 May; 22(5):549-72. PubMed ID: 10868554
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic study of human immunodeficiency virus protease inhibitors used in combination with amprenavir.
Sadler BM; Gillotin C; Lou Y; Eron JJ; Lang W; Haubrich R; Stein DS
Antimicrob Agents Chemother; 2001 Dec; 45(12):3663-8. PubMed ID: 11709366
[TBL] [Abstract][Full Text] [Related]
7. Single-dose safety and pharmacokinetics of amprenavir (141W94), a human immunodeficiency virus type 1 (HIV-1) protease inhibitor, in HIV-infected children.
Yogev R; Kovacs A; Chadwick EG; Homans JD; Lou Y; Symonds WT
Antimicrob Agents Chemother; 2005 Jan; 49(1):336-41. PubMed ID: 15616313
[TBL] [Abstract][Full Text] [Related]
8. Safety and pharmacokinetics of amprenavir (141W94), a human immunodeficiency virus (HIV) type 1 protease inhibitor, following oral administration of single doses to HIV-infected adults.
Sadler BM; Hanson CD; Chittick GE; Symonds WT; Roskell NS
Antimicrob Agents Chemother; 1999 Jul; 43(7):1686-92. PubMed ID: 10390223
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic and safety evaluation of high-dose combinations of fosamprenavir and ritonavir.
Shelton MJ; Wire MB; Lou Y; Adamkiewicz B; Min SS
Antimicrob Agents Chemother; 2006 Mar; 50(3):928-34. PubMed ID: 16495253
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of concurrent administration of fosamprenavir and atazanavir without ritonavir in human immunodeficiency virus-negative subjects.
McRae M; Clay PG; Anderson PL; Glaros AG
Pharmacotherapy; 2009 Aug; 29(8):937-42. PubMed ID: 19637947
[TBL] [Abstract][Full Text] [Related]
11. Six-week randomized controlled trial to compare the tolerabilities, pharmacokinetics, and antiviral activities of GW433908 and amprenavir in human immunodeficiency virus type 1-infected patients.
Wood R; Arasteh K; Stellbrink HJ; Teofilo E; Raffi F; Pollard RB; Eron J; Yeo J; Millard J; Wire MB; Naderer OJ
Antimicrob Agents Chemother; 2004 Jan; 48(1):116-23. PubMed ID: 14693528
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetic interaction between amprenavir and delavirdine: evidence of induced clearance by amprenavir.
Tran JQ; Petersen C; Garrett M; Hee B; Kerr BM
Clin Pharmacol Ther; 2002 Dec; 72(6):615-26. PubMed ID: 12496743
[TBL] [Abstract][Full Text] [Related]
13. Clinical pharmacology and pharmacokinetics of amprenavir.
Sadler BM; Stein DS
Ann Pharmacother; 2002 Jan; 36(1):102-18. PubMed ID: 11816239
[TBL] [Abstract][Full Text] [Related]
14. Single-dose pharmacokinetics of amprenavir, a human immunodeficiency virus type 1 protease inhibitor, in subjects with normal or impaired hepatic function.
Veronese L; Rautaureau J; Sadler BM; Gillotin C; Petite JP; Pillegand B; Delvaux M; Masliah C; Fosse S; Lou Y; Stein DS
Antimicrob Agents Chemother; 2000 Apr; 44(4):821-6. PubMed ID: 10722476
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic and pharmacodynamic analysis of amprenavir-containing combination therapy in HIV-1-infected children.
Stein DS; Lou Y; Johnson M; Randall S; Blanche S;
J Clin Pharmacol; 2004 Nov; 44(11):1301-8. PubMed ID: 15496648
[TBL] [Abstract][Full Text] [Related]
16. Effect of high-dose vitamin C on the steady-state pharmacokinetics of the protease inhibitor indinavir in healthy volunteers.
Slain D; Amsden JR; Khakoo RA; Fisher MA; Lalka D; Hobbs GR
Pharmacotherapy; 2005 Feb; 25(2):165-70. PubMed ID: 15767232
[TBL] [Abstract][Full Text] [Related]
17. Combination therapy with amprenavir, abacavir, and efavirenz in human immunodeficiency virus (HIV)-infected patients failing a protease-inhibitor regimen: pharmacokinetic drug interactions and antiviral activity.
Falloon J; Piscitelli S; Vogel S; Sadler B; Mitsuya H; Kavlick MF; Yoshimura K; Rogers M; LaFon S; Manion DJ; Lane HC; Masur H
Clin Infect Dis; 2000 Feb; 30(2):313-8. PubMed ID: 10671334
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics and pharmacodynamics of methadone enantiomers after coadministration with fosamprenavir-ritonavir in opioid-dependent subjects.
Cao YJ; Smith PF; Wire MB; Lou Y; Lancaster CT; Causon RC; Bigelow GE; Martinez E; Fuchs EJ; Radebaugh C; McCabe S; Hendrix CW
Pharmacotherapy; 2008 Jul; 28(7):863-74. PubMed ID: 18576901
[TBL] [Abstract][Full Text] [Related]
19. Interactions between amprenavir and the lopinavir-ritonavir combination in heavily pretreated patients infected with human immunodeficiency virus.
Taburet AM; Raguin G; Le Tiec C; Droz C; Barrail A; Vincent I; Morand-Joubert L; Chêne G; Clavel F; Girard PM
Clin Pharmacol Ther; 2004 Apr; 75(4):310-23. PubMed ID: 15060509
[TBL] [Abstract][Full Text] [Related]
20. In vivo effect of alpha(1)-acid glycoprotein on pharmacokinetics of amprenavir, a human immunodeficiency virus protease inhibitor.
Sadler BM; Gillotin C; Lou Y; Stein DS
Antimicrob Agents Chemother; 2001 Mar; 45(3):852-6. PubMed ID: 11181371
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
